BridgeBio Pharma (BBIO) Short term Debt (2020 - 2026)
BridgeBio Pharma's (BBIO) quarterly Short term Debt came in at $547.5 million in Q1 2026, up 14915.99% quarter-over-quarter from $3.6 million in Q1 2021.
BridgeBio Pharma (BBIO) Short term Debt (2020 - 2026) Analysis & Trends
BridgeBio Pharma has disclosed Short term Debt across 3 years of filings, most recently posting $547.5 million for Q1 2026.
- Short term Debt for Q1 2026 came in at $547.5 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $547.5 million (changed N/A YoY), and the FY2020 annual result was $1.5 million, changed N/A from the prior year.
- Short term Debt came in at $547.5 million for Q1 2026 at BridgeBio Pharma, up from $3.6 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $547.5 million in Q1 2026 to a low of $547.5 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | BridgeBio Pharma | 12.90 Bn | 11.97 Bn | 184.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 547.48 Mn |
| Mar 31, 2021 | 3.65 Mn |
| Dec 31, 2020 | 1.46 Mn |